- Home
- TURN vs VYNE Comparison
TURN vs VYNE Comparison
Compare TURN & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- VYNE
- Stock Information
- Founded
- TURN 1981
- VYNE 2003
- Country
- TURN United States
- VYNE United States
- Employees
- TURN N/A
- VYNE N/A
- Industry
- TURN Finance/Investors Services
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- VYNE Health Care
- Exchange
- TURN Nasdaq
- VYNE Nasdaq
- Market Cap
- TURN 35.3M
- VYNE 35.7M
- IPO Year
- TURN N/A
- VYNE 2018
- Fundamental
- Price
- TURN $3.80
- VYNE $1.84
- Analyst Decision
- TURN
- VYNE Strong Buy
- Analyst Count
- TURN 0
- VYNE 2
- Target Price
- TURN N/A
- VYNE $6.88
- AVG Volume (30 Days)
- TURN 43.7K
- VYNE 172.8K
- Earning Date
- TURN 05-12-2025
- VYNE 05-08-2025
- Dividend Yield
- TURN N/A
- VYNE N/A
- EPS Growth
- TURN N/A
- VYNE N/A
- EPS
- TURN N/A
- VYNE N/A
- Revenue
- TURN $194,813.00
- VYNE $501,000.00
- Revenue This Year
- TURN N/A
- VYNE N/A
- Revenue Next Year
- TURN N/A
- VYNE N/A
- P/E Ratio
- TURN N/A
- VYNE N/A
- Revenue Growth
- TURN 254.25
- VYNE 18.16
- 52 Week Low
- TURN $3.12
- VYNE $1.44
- 52 Week High
- TURN $4.20
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- TURN 51.81
- VYNE 52.41
- Support Level
- TURN $3.59
- VYNE $1.75
- Resistance Level
- TURN $3.94
- VYNE $1.89
- Average True Range (ATR)
- TURN 0.34
- VYNE 0.16
- MACD
- TURN 0.02
- VYNE 0.06
- Stochastic Oscillator
- TURN 73.03
- VYNE 74.07
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.